A PHASE 1/2A, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTI-CENTRE STUDY ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF FM101 IN PATIENTS WITH OCULAR HYPERTENSION, AND TO ASSESS THE RELATIVE BIOAVAILABILITY OF THE FM101 ORAL TABLET FORMULATION IN HEALTHY PARTICIPANTS.
The Lions Eye Institute will only be recruiting to the Phase 2A for patients with Ocular Hypertension.
Principal Investigator: Dr Antony Clark
For further information about this study, you may visit the Clinical Trials Registry or contact the Lions Eye Institute Clinical Trials Office on (08) 9381 0750 or clinicalresearch@staging.lei.org.au.
